アフターアワーズ： 5.88 0.03 +0.51%

Mind Medicine Inc (MNMD)

Mind Medicine Inc (MNMD) 最新ニュース

Mind Medicine Inc (MNMD)

Mind Medicine Inc (MNMD) 最新ニュース

MindMed executive sells over $26k in company stock By Investing.com - Investing.com Australia

MindMed CEO Robert Barrow sells shares worth over $118,000 - Investing.com

MindMed executive sells shares worth over $14k - Investing.com India

MindMed CEO Robert Barrow sells shares worth over $118,000 By Investing.com - Investing.com UK

Generalized Anxiety Disorder Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, MOA, ROA by DelveInsight | Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, MindMed, VistaGen Pharma - Barchart

Rhumbline Advisers Invests $679,000 in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat

Generalized Anxiety Disorder Global Market is Booming Across - openPR

(MNMD) Proactive Strategies - Stock Traders Daily

Mankind Pharma: Rs 10000 crore fund raise via this routeDetails - ET Now

Mankind Pharma to raise up to ₹10,000 crore through NCDs - CNBCTV18

Mankind Pharma board approves up to Rs 10,000-crore fund raise via NCDs, CPs - Moneycontrol

Mount Sinai Opens New Psychedelic Research Center in NYC - Mirage News

Psychedelic research at a crossroads - Science

Director GRYSKA DAVID W acquired 3,500 shares of Mind Medicine Inc [MNMD] - Knox Daily

Bank of New York Mellon Corp Buys 203,216 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat

Wall Street analysts’ outlook for Mind Medicine Inc (MNMD) - SETE News

Examining the Potential Price Growth of Mind Medicine Inc (MNMD) - Knox Daily

Long Strange Trip Continues for Psychedelics in PTSD, TRD - Managed Healthcare Executive

A closer look at Mind Medicine Inc (MNMD)’s stock price trends - US Post News

Mind Medicine (MindMed) (NASDAQ:MNMD) Given New $14.00 Price Target at Canaccord Genuity Group - Defense World

Mannkind Corp (MNKD) gets rating Resumed from Leerink Partners - Knox Daily

Mind Medicine (MindMed) (NASDAQ:MNMD) PT Lowered to $14.00 at Canaccord Genuity Group - MarketBeat

Trend Tracker for (MNMD) - Stock Traders Daily

MindMed Issues New Employee Share Options - TipRanks

MindMed Announces New Employee Inducement Grants - Business Wire

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Average Rating of "Buy" by Analysts - MarketBeat

MindMed Showcases Innovation at Investor Events - TipRanks

MindMed to Participate in September Investor Conferences - StockTitan

MindMed to Participate in September Investor Conferences - Yahoo Finance

Mind Medicine (MindMed) Inc. Expected to Earn Q3 2024 Earnings of ($0.27) Per Share (NASDAQ:MNMD) - MarketBeat

Mind Medicine (MindMed) (NASDAQ:MNMD) Price Target Raised to $55.00 - MarketBeat

(MNMD) Long Term Investment Analysis - Stock Traders Daily

Mind medicine director David Gryska buys $20,930 in company shares By Investing.com - Investing.com Canada

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Director Acquires $20,930.00 in Stock - MarketBeat

Mind medicine director David Gryska buys $20,930 in company shares By Investing.com - Investing.com Australia

Mind medicine director David Gryska buys $20,930 in company shares - Investing.com India

Mind medicine director David Gryska buys $20,930 in company shares - Investing.com

Mind medicine director David Gryska buys $20,930 in company shares By Investing.com - Investing.com UK

Mind Medicine Inc’s $75 Million Common Shares Offering - Global Legal Chronicle

Mind Medicine: Pumping Up The Balance Sheet (Again) (NASDAQ:MNMD) - Seeking Alpha

Mind Medicine CEO Robert Barrow buys $6,215 in shares - Investing.com India

Mind Medicine CEO Robert Barrow buys $6,215 in shares - Investing.com

Mind Medicine CEO Robert Barrow buys $6,215 in shares By Investing.com - Investing.com UK

Mind Medicine Highlights GAD’s Economic Impact - TipRanks

MindMed to Showcase at Neuro Conference - TipRanks

MindMed to Engage in Canaccord Genuity Growth Event - TipRanks

MindMed to Present at Oppenheimer Healthcare Conference - TipRanks

MindMed Unveils GAD Treatment Study at Key Conferences - TipRanks

MNMD (Mind Medicine) EV-to-Revenue : (As of Aug. 19, 2024) - GuruFocus.com

Vanguard Group Inc. Reduces Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Defense World

Mind Medicine (NEOE:MMED) Cash-to-Debt : 10.03 (As of Jun. 2024) - GuruFocus.com

MNMD (Mind Medicine) Intrinsic Value: DCF (Earnings Based) : $-24.41 (As of Aug. 16, 2024) - GuruFocus.com

Brokers Issue Forecasts for Mind Medicine (MindMed) Inc.'s Q3 2024 Earnings (NASDAQ:MNMD) - MarketBeat

Q3 2024 Earnings Estimate for Mind Medicine (MindMed) Inc. Issued By Leerink Partnrs (NASDAQ:MNMD) - Defense World

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Forecasted to Post Q3 2024 Earnings of ($0.31) Per Share - Defense World

Psychedelic Stocks: Focus On Their Cash - Seeking Alpha

Hogan Lovells Guides Mind Medicine Inc. on its US$75m Underwritten Public Offering - Legal Desire News Network

Small Cap Stocks: Mind Medicine (MNMD) Is a Psychedelic Biotechnology Bet - Nasdaq

Mind Medicine (MindMed) (OTCMKTS:MMEDF) Stock Price Down 3.8% - Defense World

Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap Up to $6.85 - MarketBeat

MindMed Reports Second Quarter 2024 Financial Results and Business Updates - citybiz

MNMD Stock Earnings: Mind Medicine Misses EPS for Q2 2024 - InvestorPlace

MindMed Advances MM120 Trials with Strong Finances - TipRanks

MindMed reassures investors with its cash cushion for drug studies - Green Market Report

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering - Manchestertimes

MindMed Reports Second Quarter 2024 Financial Results and Business Updates - Business Wire

MNMDに似た銘柄